The Europe Herpes Simplex Virus Treatment Market would witness market growth of 2.8% CAGR during the forecast period (2022-2028).
The pipeline of vaccine candidates is anticipated to be released on the market throughout the forecast period. For example, GSK is working on the GSK4108771A vaccine, Sanofi Pasteur is developing the HSV529 vaccine, and RVx201 is a vaccine for HSV-2 that is a live attenuated vaccine. Moreover, EXD-12 is now undergoing preclinical testing. Moreover, efforts are being made by significant market participants to create and market vaccine candidates that are appropriate for herpes infection. For instance, research is being done to create highly effective, safe, and effective mRNA vaccine candidates. For instance, Moderna Inc. is working on mRNA-1608, a candidate for an mRNA vaccine.
Additionally, the efficiency and simplicity of administration of oral medication for herpes have significantly increased their demand. Oral versions of acyclovir, famciclovir, and valacyclovir are offered. Acyclovir, when taken orally, also lessens the average length of cold sore pain compared to a placebo, according to multiple research. In addition, acyclovir, administered orally, has a faster healing period than other therapy formulations. Moreover, oral formulations aid in delivering quick action, improving its appeal among the populace.
The prevalence of HSV-1 infection among young adults is lower in Northern European nations. European women are far more likely than European men to be HSV-1 seropositive. Although there are significant variances in the proportion of people exposed to HSV-2, HSV-2 seropositivity is commonly found among Europeans over 12 years of age. Compared to other European nations, Bulgaria has a high HSV-2 seroprevalence. In every European nation, HSV-2 seropositivity rises with age and becomes more prevalent in the population, with some nations seeing a reduction in the older age groups. Therefore, the increasing prevalence of HSV infections and the research initiatives looking for better medications will drive the regional market's growth in the coming years.
The Germany market dominated the Europe Herpes Simplex Virus Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $140.9 Million by 2028. The UK market is anticipated to grow at a CAGR of 1.9% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 3.5% during (2022 - 2028).
Based on Drug Type, the market is segmented into Valacyclovir, Acyclovir, and Famciclovir. Based on Type, the market is segmented into Herpes simplex virus-1 Infection, and Herpes simplex virus-2 Infection. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Herpes Simplex Virus Treatment Market will Hit $2.1 Billion by 2028, at a CAGR of 3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Pfizer, Inc., Amneal Pharmaceuticals, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Limited, Fresenius SE & Co. KGaA, Novartis AG, Viatris, Inc., and Emcure Pharmaceuticals Limited.
By Drug Type
By Type
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
